The Contract Research and Manufacturing Services (CRAMS) side of the business has contributed to the June quarter bottomline on the back of good product mix, says Venkat Jasti, CEO, Suven Life Sciences.
first published: Aug 11, 2016 11:49 am
A collection of the most-viewed Moneycontrol videos.

Live: Nifty registers third straight week of gains, up 2% in November | Closing Bell

Live: Can Nifty continue to step up its move to fresh peaks? | Opening Bell

Live: Sensex, Nifty retreat after mounting on new lifetime highs | Closing Bell

Live: Will bulls take Nifty to fresh lifetime highs today? | Opening Bell
You are already a Moneycontrol Pro user.

